AnaptysBio Q2 FY26 net income from continuing operations more than doubles to $177.3 million; revenue rises 23.5% to $27.49 million

By Public Technologies
  • AnaptysBio posted Q2 net income from continuing operations of USD 177.3 million, versus USD 5.7 million a year earlier.
  • Q2 collaboration revenue rose 23.47% year over year to USD 27.49 million, while general and administrative expenses climbed to USD 16.04 million.
  • Cash, cash equivalents and investments totaled USD 164.1 million at June 30, down from USD 211.6 million at Dec. 31, 2025.
  • Management flagged Jemperli global net sales of USD 644 million for the six months ended June 30, up 34% year over year.
  • Updates include a Feb. 2027 FDA PDUFA date for Jemperli in rectal cancer and a Dec. 12, 2026 PDUFA date for Quimilza in GPP.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609211615PRIMZONEFULLFEED9830768) on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.